Loading
Emavusertib is an oral serine/threonine kinase inhibitor from Curis, Inc., in registered phase 2 trials for chronic lymphocytic leukaemia, brain and spinal cord tumours.
Emavusertib is listed on ClinicalTrials.gov as an intervention in 2 registered phase 2 trials sponsored by Curis, Inc., in chronic lymphocytic leukaemia, brain and spinal cord tumours. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.
1.Emavusertib slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Emavusertib" OR ABSTRACT:"Emavusertib" OR TITLE:"CA-4948" OR ABSTRACT:"CA-4948") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Emavusertib, not a curated reading list.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.